Compare Atomera Incorporated (ATOM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atomera Incorporated vs TG Therapeutics Inc — how do they compare? Atomera Incorporated trades at $5.62 (market cap $217.36M), while TG Therapeutics Inc trades at $50.5 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 35.1× Atomera Incorporated's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Atomera Incorporated nearer its low. Which is the better fit depends on your goals.
| ATOM | TGTX | |
|---|---|---|
Market Cap | $217.36M | $7.64B |
Sector | Technology | Health |
52-Week High | $12.11 | $59.06 |
52-Week Low | $1.99 | $26.94 |
Enterprise Value | $180.18M | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ATOM trades at $5.68, up 5.77% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of $158,000, missing earnings expectations with a net loss of $22 million. Despite negative profitability metrics, analyst consensus is 100% buy, reflecting optimism around semiconductor technology advancements like GaN-on-Silicon for RF applications.
The outlook hinges on commercial adoption of its licensing technology, but significant risks persist from sustained losses, high cash burn, and competitive pressures. Investment potential lies in breakthrough adoption, though current fundamentals indicate speculative high-risk exposure for equity investors.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
